ADHD Medication's Long-Term Safety Confirmed
Complete the form below to unlock access to ALL audio articles.
Methylphenidate was rejected by the World Health Organization (WHO) for inclusion in their Essential Medicines List due to concerns regarding the quality and limitations of the available evidence for both benefit and harm.
However, the Attention-Deficit-Hyperactivity-Disorder-Drugs-Use-Chronic-Effects (ADDUCE) project has revealed that methylphenidate does not increase the risk of growth impairments, psychiatric or neurological adverse events in children and adolescents.
The two-year study, which was originally run from the University of Dundee, included 1410 children from 27 child and adolescent mental health centres in the UK, Germany, Switzerland, Italy and Hungary. This included more than 270 from Dundee, who were enrolled in the Child and Mental Health Service (CAMHS) and Ninewells Hospital.
Want more breaking news?
Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.Subscribe for FREE
The study findings have been published in The Lancet Psychiatry.
Dr Sarah Inglis, from the University’s School of Medicine, who was the project/trial manager for the ADDUCE study, said, “The use of methylphenidate has gone up greatly since it was licensed in the 1950s and yet information about side effects from long-term use is scarce.
“We observed the characteristics of a large number of children with ADHD across Europe, including 274 from Dundee, taking methylphenidate over a period of two years. We compared these characteristics with children with ADHD not taking methylphenidate, and with children without ADHD.
“The study shows that the growth rate of children taking methylphenidate over two years was not different to that of children who were not. There was no adverse effect on mental health.
“WHO has previously rejected calls for methylphenidate to be included in their Essential Medicines List due to ‘concerns regarding the quality and limitations of the available evidence for both benefit and harm’. The results of the ADDUCE study provide supportive evidence for inclusion of methylphenidate on this list, which would increase the availability of the medicine and support more children around the world with ADHD.”
Reference: Man KKC, Häge A, Banaschewski T, et al. Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study. Lancet Psychiatry. 2023;10(5):323-333. doi: 10.1016/S2215-0366(23)00042-1
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.